20110141.LumB
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- ESTROGEN_RESPONSE_EARLY+0.400
- OXIDATIVE_PHOSPHORYLATION+0.390
- ESTROGEN_RESPONSE_LATE+0.350
- DNA_REPAIR+0.290
- PROTEIN_SECRETION+0.290
- BILE_ACID_METABOLISM+0.250
- PEROXISOME+0.250
- MYC_TARGETS_V1+0.230
- FATTY_ACID_METABOLISM+0.210
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- HEDGEHOG_SIGNALING-0.450
- MYC_TARGETS_V2-0.440
- NOTCH_SIGNALING-0.400
- HYPOXIA-0.360
- TNFA_SIGNALING_VIA_NFKB-0.330
- ANGIOGENESIS-0.320
- APICAL_JUNCTION-0.320
- MITOTIC_SPINDLE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A1FG-01A-11R-A13Q-07 | — | B | 0.815 |
| 2 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.782 |
| 3 | 20040027.LumB | — | C | 0.773 |
| 4 | TCGA-C8-A133-01A-32R-A12D-07 | — | B | 0.757 |
| 5 | 20070010.LumB | — | B | 0.756 |
| 6 | MNG85 | — | — | 0.750 |
| 7 | TCGA-E2-A15E-06A-11R-A12D-07 | — | B | 0.750 |
| 8 | SRR25617939 | — | B | 0.746 |
| 9 | TCGA-D8-A1JT-01A-31R-A13Q-07 | — | B | 0.734 |
| 10 | SRR29022827 | — | C | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |